ProShares UltraPro Short NASDAQ Biotechnology
ZBIO
ZBIO was delisted on the 27th of March, 2020.
6 hedge funds and large institutions have $4.36M invested in ProShares UltraPro Short NASDAQ Biotechnology in 2016 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.
110% more capital invested
Capital invested by funds: $2.08M → $4.36M (+$2.28M)
14% less funds holding
Funds holding: 7 → 6 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
64% less call options, than puts
Call options by funds: $857K | Put options by funds: $2.35M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
+$1.95M |
| 2 |
EDRS
Edmond de Rothschild (Suisse)
Geneva,
Switzerland
|
+$1.95M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$30.5K |
| 4 |
IA
IFP Advisors
Tampa,
Florida
|
+$23.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$391K |
| 2 |
Morgan Stanley
New York
|
-$181K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$175K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$33K |
| 5 |
CG
Cutler Group
San Francisco,
California
|
-$2.31K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
EDRH
1
Edmond de Rothschild Holding
Chambesy,
Switzerland
| $1.78M | +$1.95M | +42,233 | New |
|
|
EDRS
2
Edmond de Rothschild (Suisse)
Geneva,
Switzerland
| $1.78M | +$1.95M | +42,233 | New |
|
|
VF
3
Virtu Financial
New York
| $496K | -$391K | -8,465 | -42% |
|
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $259K | +$30.5K | +660 | +12% |
|
|
IA
5
IFP Advisors
Tampa,
Florida
| $21K | +$23.1K | +500 | New |
|
|
CG
6
Cutler Group
San Francisco,
California
| $16K | -$2.31K | -50 | -11% |
|
|
7
Morgan Stanley
New York
| – | -$181K | -2,795 | Closed |
|
|
8
Simplex Trading
Chicago,
Illinois
| – | -$175K | -2,720 | Closed |
|
|
9
UBS Group
Zurich,
Switzerland
| – | -$33K | -505 | Closed |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| – | -$1K | -22 | Closed |
|
ZBIO Hedge Fund Activity: Q3 2016 in Review
6 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) for Q3 2016, worth a combined $4.36M — up 110% from $2.08M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ZBIO and 3 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 1 added.
The largest buyer was Edmond de Rothschild Holding, opening a new position worth an estimated $1.95M. The largest seller was Virtu Financial, cutting an estimated $391K.
- 6 institutional investors held ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) as of Q3 2016, down from 7 in Q2 2016.
- Funds reported $4.36M of ProShares UltraPro Short NASDAQ Biotechnology stock for Q3 2016, up 110% quarter-over-quarter.
- 3 funds opened new ProShares UltraPro Short NASDAQ Biotechnology positions in Q3 2016 and 4 closed out, a net change of -1 holder.
- The largest ProShares UltraPro Short NASDAQ Biotechnology buyer in Q3 2016 was Edmond de Rothschild Holding, an estimated $1.95M added.
- The largest ProShares UltraPro Short NASDAQ Biotechnology seller in Q3 2016 was Virtu Financial, an estimated $391K sold.
Based on aggregated 13F filings for Q3 2016.